Biology Reference
In-Depth Information
Butt E, Beltman J, Becker DE, Jensen GS, Rybalkin SD, Jastorff B, Beavo JA (1995a) Characteri-
zation of cyclic nucleotide phosphodiesterases with cyclic GMP analogs: topology of the
catalytic domains. Mol Pharmacol 47:330-339
Butt E, Beltman J, Becker DE, Jensen GS, Rybalkin SD, Jastorff B, Beavo JA (1995b) Characteri-
zation of cyclic nucleotide phosphodiesterases with cyclic AMP analogs: topology of the
catalytic sites and comparison with other cyclic AMP-binding proteins. Mol Pharmacol
47:340-347
Conti M, Beavo J (2007) Biochemistry and physiology of cyclic nucleotide phosphodiesterases:
essential components in cyclic nucleotide signaling. Annu Rev Biochem 76:481-511
Fisher DA, Smith JF, Pillar JS, St Denis SH, Cheng JB (1998) Isolation and characterization of
PDE9A, a novel human cGMP-specific phosphodiesterase. J Biol Chem 273:15559-15564
Francis SH, Zoraghi R, Kotera J, Ke H, Bessay EP, Blouni MA, Corbin JD (2006) Phoephodies-
terase 5: Molecular characteristics relating to structure, function, and regulation. In: Beavo JA,
Francis SH, Houslay MS (eds) Cyclic nucleotide phosphodiesterases in health and disease.
CRC Press, Boca Raton, FL, pp 131-164
Hannila SS, Filbin MT (2008) The role of cyclic AMP signaling in promoting axonal regeneration
after spinal cord injury. Exp Neurol 209:321-332
Hitchcock M (1973) Adenosine 3', 5'-cyclic monophosphate phosphodiesterase in guineq-pig
lung-properties and effect of adrenergic drugs. Biochem Pharmacol 22:959-969
Horvath A, Stratakis CA (2008) Unraveling the molecular basis of micronodular adrenal hyper-
plasia. Curr Opin Endocrinol Diabetes Obes 15:227-233
Houslay MD (1998) Adaptation in cyclic AMP signaling processes: a central role for cyclic AMP
phosphodiesterases. Cell Develop Biol 9:161-167
Huai Q, Colicelli J, Ke H (2003) The crystal structure of AMP-bound PDE4 suggests a mechanism
for phosphodiesterase catalysis
{
,
. Biochemistry 42:13220-13226
Huai Q, Wang H, Zhang W, Colman R, Robinson H, Ke H (2004) Crystal structure of phosphodi-
esterase 9 shows orientation variation of inhibitor 3-isobutyl-1-methylxanthine binding. Proc
Natl Acad Sci USA 101:9624-9629
Iffland A, Kohls D, Low S, Luan J, Zhang Y, Kothe M, Cao Q, Kamath AV, Ding YH, Ellenberger
T (2005) Structural determinants for inhibitor specificity and selectivity in PDE2A using the
wheat germ in vitro translation system. Biochemistry 44:8312-8325
Lee CH, Evans FE, Sarma RH (1975) Interaction between glycosidic torsion, sugar pucker, and
backbone conformation in 5
0
-b-nucleotides. J Biol Chem 250:1290-1296
Liu S, Mansour MN, Dillman KS, Perez JR, Danley DE, Aeed PA, Simons SP, Lemotte PK,
Menniti FS (2008) Structural basis for the catalytic mechanism of human phosphodiesterase 9.
Proc Natl Acad Sci USA 105:13309-13314
Lugnier C (2006) Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the
development of specific therapeutic agents. Pharmacol Ther 109:366-398
Mehats C, Andersen CB, Filopanti M, Jin SL, Conti M (2002) Cyclic nucleotide phosphodies-
terases and their role in endocrine cell signaling. Trends Endocrinol Metab 13:29-35
Monn E, Christiansen RO (1971) Adenosine 3
0
,5
0
-monophosphate phosphodiesterase: multiple
molecular forms. Science 173:540-542
Omori K, Kotera J (2007) Overview of PDEs and their regulation. Circ Res 100:309-327
O'Neill JS, Maywood ES, Chesham JE, Takahashi JS, Hastings MH (2008) cAMP-dependent
signaling as a core component of the mammalian circadian pacemaker. Science 320:949-953
Piper M, van Horck F, Holt C (2007) The role of cyclic nucleotides in axon guidance. Adv Exp
Med Biol 621:134-143
Scapin G, Patel SB, Chung C, Varnerin JP, Edmondson SD, Mastracchio A, Parmee ER, Singh SB,
Becker JW, Van der Ploeg LH, Tota MR (2004) Crystal structure of human phosphodiesterase
3B: atomic basis for substrate and inhibitor specificity. Biochemistry 43:6091-6100
Soderling SH, Bayuga SJ, Beavo JA (1998) Identification and characterization of a novel family of
cyclic nucleotide phosphodiesterases. J Biol Chem 273:15553-15558
{
